Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis.
Dereck R TaitMark HatherillOlivier Van Der MeerenAnn M GinsbergElana Van BrakelBruno SalaunThomas J ScribaElaine J AkiteHelen M AylesAnne BollaertsMarie-Ange DemoitiéAndreas DiaconThomas G EvansPaul GillardElizabeth HellströmJames C InnesMaria LempickiMookho MalahlehaNeil MartinsonDoris Mesia VelaMonde MuyoyetaVidelis NdubaThierry G PascalMichele TamerisFriedrich ThienemannRobert J WilkinsonFrançois RomanPublished in: The New England journal of medicine (2019)
Among adults infected with M. tuberculosis, vaccination with M72/AS01E elicited an immune response and provided protection against progression to pulmonary tuberculosis disease for at least 3 years. (Funded by GlaxoSmithKline Biologicals and Aeras; ClinicalTrials.gov number, NCT01755598.).